AH23848 was identified as a potent, specific, orally active thromboxane receptor-blocking drug with a long duration of action in preliminary experiments.
AH23848 is a novel, orally active, and specific thromboxane receptor blocker that may serve as a tool to study the role of thromboxane A2 in vascular diseases.
Despite numerous suggestions in the literature that thromboxane A2 is involved in a variety of occlusive vascular diseases, no definitive evidence is available. Arguments have been presented to support the view that such evidence can only come from clinical studies with a highly specific thromboxane receptor-blocking drug. We have now identified such a drug, AH23848, in our laboratories. Preliminary experiments with AH23848, (1 alpha (Z), 2 beta,5 alpha-(+/-)-7-5-[[(1,1'-biphenyl)-4-ylmethoxy]-2-(4-morpholin yl)-3-oxocyclopentyl]-4-heptenoic acid), show that it is a potent, specific thromboxane receptor-blocking drug that is orally active and has a long duration of action. It should be a valuable tool in elucidating any physiologic or pathologic role of thromboxane A2.
Brittain et al. (1985) studied occlusive vascular diseases. AH23848 was evaluated. AH23848 was identified as a potent, specific, orally active thromboxane receptor-blocking drug with a long duration of action in preliminary experiments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: